Effect of atorvastatin on IgA nephropathy in the rat

Clinical Nephrology

Volumn 79, Issue 3, 2013, Pages 214-220

  Katzir, Ze'ev ^a   Leibovitch, Elena ^a   Vaknin, Hanan ^b   Schreiber, Letizia ^b   Berger, Esther ^b   Matas, Zipora ^c   Fux, Asora ^c   Boaz, Mona ^d   Briliant, Alexander ^a   Biro, Alexander ^a  

^a Institute of Nephrology   (Israel)

^b Institute of Pathology   (Israel)

^c Biochemistry Laboratory   (Israel)

^d WOLFSON MEDICAL CENTER   (Israel)

Author keywords

IgA nephropathy; Statin

Indexed keywords

ATORVASTATIN; CREATININE; IMMUNOGLOBULIN; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFECT; GLOMERULUS FILTRATION; HISTOPATHOLOGY; IMMUNOFLUORESCENCE; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FUNCTION; MALE; NONHUMAN; PROTEINURIA; RAT; UREA BLOOD LEVEL; URINE VOLUME;

ANIMALS; CREATININE; FLUORESCENT ANTIBODY TECHNIQUE; GLOMERULONEPHRITIS, IGA; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY; MALE; PYRROLES; RATS; RATS, INBRED WKY;

EID: 84874983220     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN107621     Document Type: Article

References (37)

1. D'Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med. 1987; 64: 709-727. PubMed
2. D'Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis. 2000; 36: 227-237. doi:10.1053/ajkd.2000.8966 PubMed
3. Eitner F, Ackermann D, Hilgers RD, Floege J. Supportive Versus Immunosuppressive Therapy of Progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol. J Nephrol. 2008; 21: 284-289. PubMed
4. Tumlin JA, Lohavichan V, Hennigar R. Crescenteric, proliferative IgA nephropathy: response to methylprednisolone and intravenous cyclophosphamide. Nephrol Dial Transplant. 2003; 18: 1321-1329. doi:10.1093/ndt/gfg081 PubMed
5. Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P, Ponticelli C, Locatelli F. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol. 2004; 15: 157-163. doi:10.1097/01.ASN.0000103869.08096.4F PubMed
6. Frisch G, Lin J, Rosenstock J, Markowitz G, D'Agati V, Radhakrishnan J, Preddie D, Crew J, Valeri A, Appel G. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol Dial Transplant. 2005; 20: 2139-2145. doi:10.1093/ndt/gfh974 PubMed
7. Stangou M, Ekonomidou D, Giamalis P, Liakou H, Tsiantoulas A, Pantzaki A, Papagianni A, Efstratiadis G, Alexopoulos E, Memmos D. Steroids and azathioprine in the treatment of IgA nephropathy. Clin Exp Nephrol. 2011; 15: 373-380.
8. Yuansheng X, Huang S, Wang L, Miao L, Zhang A, Li Y, Wu X, Wang L, Liu S, Lie C, Chen P, Chen X. Efficacy and safety of mizoribine combined with losartan in the treatment of IgA nephropathy: a multicenter, randomized, controlled study. Am J Med Sci. 2011; 20: 1-6.
9. Moriyama T, Amamiya N, Ochi A, Tsuruta Y, Shimizu A, Kojima C, Itabashi M, Takei T, Uchida K, Nitta K. Long-term beneficial effects of angiotensin- converting enzyme inhibitor and angiotensin receptor blocker therapy for patients with advanced immunoglobulin A nephropathy and impaired renal function. Clin Exp Nephrol. 2011; 15: 700-707. doi:10.1007/s10157-011-0455-8 PubMed
10. Bang K, Chin HJ, Chae DW, Joo KW, Kim YS, Kim S, Ju KD, Kim H, Ahn C, Oh KH. Anti-proteinuric effect of sulodexide in immunorlobulin A nephropathy. Yonsei Med J. 2011; 52: 488-594. doi:10.3349/ymj.2011.52.4.588 PubMed
11. Downward J. Cell cycle: routine role for Ras. Curr Biol. 1997; 7: R258-R260. doi:10.1016/ S0960-9822(06)00116-3 PubMed
12. Mason JC. The statins - therapeutic diversity in renal disease? Curr Opin Nephrol Hypertens. 2005; 14: 17-24. doi:10.1097/00041552- 200501000-00004 PubMed
13. Epstein M, Campese VM. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function. Am J Kidney Dis. 2005; 45: 2-14. doi:10.1053/j. ajkd.2004.08.040 PubMed
14. Khanal S, Attallah N, Smith DE, Kline-Rogers E, Share D, O'Donnell MJ, Moscucci M. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med. 2005; 118: 843-849. doi:10.1016/j.amjmed.2005.03.031 PubMed
15. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006; 17: 2006-2016. doi:10.1681/ASN.2006010012 PubMed
16. Guijarro C, Kim Y, Schoonover CM, Massy ZA, O'Donnell MP, Kasiske BL, Keane WF, Kashtan CE. Lovastatin inhibits lipopolysaccharide-induced NF-kappaB activation in human mesangial cells. Nephrol Dial Transplant. 1996; 11: 990-996. doi:10.1093/oxfordjournals.ndt.a027522 PubMed
17. Nakamura T, Ushiyama C, Hirokawa K, Osada S, Inoue T, Shimada N, Koide H. Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis. Nephrol Dial Transplant. 2002; 17: 798-802. doi:10.1093/ ndt/17.5.798 PubMed
18. Buemi M, Allegra A, Corica F, Aloisi C, Giacobbe M, Pettinato G, Corsonello A, Senatore M, Frisina N. Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy. Clin Pharmacol Ther. 2000; 67: 427-431. doi:10.1067/ mcp.2000.105330 PubMed
19. Emancipator SN, Gallo GR, Lamm ME. Experimental IgA nephropathy induced by oral immunization. J Exp Med. 1983; 157: 572-582. doi:10.1084/jem.157.2.572 PubMed
20. Kuemmerle NB, Chan W, Krieg RJ Jr, Norkus EP, Trachtman H, Chan JCM. Effects of fish oil and a-tocopherol in immunoglobulin A nephropathy in the rat. Pediatr Res. 1998; 43: 791-797. doi:10.1203/00006450-199806000-00012 PubMed
21. Rauta V, Finne P, Fagerudd J, Rosenlöf K, Törnroth T, Grönhagen-Riska C. Factors associated with progression of IgA nephropathy are related to renal function--a model for estimating risk of progression in mild disease. Clin Nephrol. 2002; 58: 85-94. PubMed
22. Feehally J. Predicting prognosis in IgA nephropathy. Am J Kidney Dis. 2001; 38: 881-883. doi:10.1053/ajkd.2001.28767 PubMed
23. Glassock RJ. The pathogenesis of IgA nephropathy. Curr Opin Nephrol Hypertens. 2011; 20: 153-160. doi:10.1097/MNH.0b013e3283436f5c PubMed
24. Yu HH, Chu KH, Yang YH, Lee JH, Wang LC, Lin YT, Chiang BL. Genetics and immunopathogenesis of IgA nephropathy. Clin Rev Allergy Immunol. 2011; 41: 198-213. doi:10.1007/s12016-010- 8232-0 PubMed
25. Li GS, Zhang H, Lv JC, Shen Y, Wang HY. Variants of C1GALT1 gene are associated with the genetic susceptibility to IgA nephropathy. Kidney Int. 2007; 71: 448-453. doi:10.1038/sj.ki.5002088 PubMed
26. Kiryluk K, Moldoveanu Z, Sanders JT, Eison TM, Suzuki H, Julian BA, Novak J, Gharavi AG, Wyatt RJ. Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch- Schönlein purpura nephritis. Kidney Int. 2011; 80: 79-87. doi:10.1038/ki.2011.16 PubMed
27. Liu H, Peng Y, Liu F, Xiao W, Zhang Y, Li W. Expression of IgA class switching gene in tonsillar mononuclear cells in patients with IgA nephropathy. J Virol. 2011; 85: 9863-9876. doi:10.1128/ JVI.00828-11 PubMed
28. Smerud HK, Barany P, Lindstrom K, Fernstrom A, Sandell A, Pahlsson P, Fellstrom B. New treatment of IgA nephropathy: entericbudesonide targeted to the ileocecal region ameliorates proteinuria. Nephrol Dial Transplant. 2011; 0: 1-6.
29. Tomino Y. Pathogenetic and therapeutic approaches to IgA nephropathy using a spontaneous animal model, the ddY mouse. Clin Exp Nephrol. 2011; 15: 1-7. doi:10.1007/s10157-010-0359-z PubMed
30. Emancipator SN. Prospects and perspectives on IgA nephropathy from animal models. Contrib Nephrol. 2011; 169: 126-152. doi:10.115 9/ 000319124 PubMed
31. Vrtovsnik F, Couette S, Prié D, Lallemand D, Friedlander G. Lovastatin-induced inhibition of renal epithelial tubular cell proliferation involves a p21ras activated, AP-1-dependent pathway. Kidney Int. 1997; 52: 1016-1027. doi:10.1038/ ki.1997.423 PubMed
32. Buemi M, Senatore M, Corica F, Aloisi C, Romeo A, Cavallaro E, Floccari F, Tramontana D, Frisina N. Statins and progressive renal disease. Med Res Rev. 2002; 22: 76-84. doi:10.1002/med.10000 PubMed
33. O'Donnell MP, Kasiske BL, Kim Y, Atluru D, Keane WF. Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest. 1993; 91: 83-87. doi:10.1172/JCI116204 PubMed
34. Park HC, Xu ZG, Choi S, Goo YS, Kang SW, Choi KH, Ha SK, Lee HY, Han DS. Effect of losartan and amlodipine on proteinuria and transforming growth factor-beta1 in patients with IgA nephropathy. Nephrol Dial Transplant. 2003; 18: 1115- 1121. http://www.ncbi.nlm.nih.gov/ pubmed/12748343
35. Kordek R, Biernat W, Alwasiak J, Liberski PP. Proliferating nuclear cel antigen (PCNA) and Ki-67 immunopositivity in human astrocytic tumours. Pathol Res Pract. 1996; 192: 205-209. doi:10.1016/S0344-0338(96)80222-6 PubMed
36. Choong PF, Akerman M, Willén H, Andersson C, Gustafson P, Alvegård T, Rydholm A. Expression of proliferating cell nuclear antigen (PCNA) and Ki-67 in soft tissue sarcoma. Is prognostic significance histotype-specific? APMIS. 1995; 103: 797-805. doi:10.1111/j.1699-0463.1995.tb01 437.x PubMed
37. Yasuda H, Yuen PST, Hu X, Zhou H, Star RA. Simvastatin improves sepsis-induced mortality and acute kidney injury via renal vascular effects. Kidney Int. 2006; 69: 1535-1542. doi:10.1038/ sj.ki.5000300 PubMed